The regulatory gap underwriters are being asked to price
A cultivated-meat or fermentation-protein startup walks into the market with a product that has no settled legal identity. FSSAI currently treats cultivated meat as a non-specified food or ingredient, in effect a novel food, which means it cannot be manufactured, imported or sold without specific regulator approval. The approval route exists, but the substantive standards (composition, labelling, claims, permitted process inputs) are not finalised.
This is the underwriting problem in one sentence: an insurer is asked to price product liability for a product whose lawful form is still being defined. Standard product-liability rating leans on a stable picture of the product, its standards, its labelling regime and its loss history. A first-of-kind food has none of those anchors.
FSSAI's 2022 draft on cell-based meat was circulated for stakeholder comment but has not been finalised, and the regulator is developing the framework alongside the Department of Biotechnology and BIRAC. For context, FSSAI already regulates plant-based protein products and bars dairy descriptors for plant-based dairy, but lab-grown and fermentation-derived proteins sit outside any clear standard. The plant-based segment shows what a settled regime looks like; the cultivated segment shows what underwriting an unsettled one feels like.
Where the loss actually comes from
Before structuring cover, a broker should map the exposures specific to this category rather than reuse a generic food-product checklist.
- Consumer injury. A bioprocess product carries the risk of an unexpected allergen, a residual process input, or a contaminant introduced in cell culture, harvest or formulation. The injury pathway is bodily injury to a consumer, the classic product-liability trigger.
- Contamination and spoilage. Bioreactor and cold-chain processes have failure modes (microbial contamination, media or scaffold issues) that can render a batch unsafe, driving both injury claims and the cost of withdrawing stock.
- Mislabelling and claims risk. With no finalised labelling standard, a startup makes naming and claim decisions in a grey zone. A label later deemed misleading creates liability that is regulatory, contractual and reputational at once.
- First-of-kind technical risk. The science is young. A defect traced to the process or the underlying technology blurs the line between a product-liability claim and a professional or technical indemnity claim.
Building the cover stack: liability, recall and technical indemnity
No single policy answers this risk. A broker assembles a stack and makes the interfaces between policies explicit so a real loss does not fall between them.
Product liability as the base
Product liability responds to third-party bodily injury or property damage caused by a defective product. For a cultivated-protein startup this is the foundation, covering the consumer-injury pathway. The negotiation centres on the product description, the territory (domestic sale only, or export), and how broadly defect is defined.
Recall as the first-response layer
Product liability pays third parties who are harmed; it does not pay the insured's own cost of pulling a batch off shelves. That is product recall cover, which funds withdrawal, logistics, communication and sometimes replacement. For a young brand a single recall event can be existential, so recall cover is not optional bolt-on, it is core.
Technical and clinical indemnity for the science layer
Where harm traces to the process, the formulation method or advice given about the product, a professional or technical indemnity wording may be the responding policy rather than product liability. Aligning the two prevents an insurer on each side arguing the other should pay.
The broker's job is to write these as one programme: consistent insured entities, aligned territorial scope, matched definitions of the product, and a clear order of response so recall, liability and technical indemnity dovetail instead of overlapping or leaving a gap.
Why the unsettled status drives the exclusions
The hard part of these placements is rarely the headline cover. It is the exclusions and conditions that the regulatory uncertainty pushes insurers to attach.
Because the product is a non-specified food awaiting approval, an insurer will commonly seek to exclude or condition cover around regulatory status. The practical forms this takes:
- Regulatory-approval condition. Cover may apply only to product sold after the relevant FSSAI approval is in place, so anything distributed during a tasting, pilot or pre-approval phase needs separate, explicit treatment.
- Efficacy and claims carve-outs. Insurers separate bodily-injury liability (which they will consider) from liability arising purely from a product not performing or a claim not holding up, which they often will not.
- Defined-product wording. The schedule pins cover to a precisely described product and process; a material change in the process can take the new product outside the cover.
- New-technology and known-risk language. Anything the startup knew or ought to have known about a hazard before placement is liable to be excluded.
A broker reads these clauses as the live battleground. The first cultivated-meat tasting in India was held in Mumbai by Biokraft Foods, with a market launch targeted in close coordination with FSSAI, and a placement built for that journey must distinguish the tasting and pilot phase from commercial sale, because the exclusions hinge on exactly that distinction.
What the broker brings to the table
For a category with no claims history and no finalised rulebook, the placement is won on preparation, not on shopping the market for a rate.
The broker should help the startup assemble the underwriting story: the bioprocess and its controls, the contamination and allergen testing regime, the cold-chain design, the labelling and claims decisions, the recall plan, and the regulatory pathway with FSSAI. Underwriters pricing an unprecedented risk lean heavily on the credibility of these controls, so a clear risk narrative directly shapes both the terms offered and the breadth of the exclusions.
The broker also manages expectations. First-of-kind cover is likely to come with lower limits, tighter conditions and a defined product description, and the right posture is to secure a defensible programme now and broaden it as the regulatory framework settles and a loss history forms. As FSSAI finalises standards, the basis of cover can move from heavily conditioned to more standardised, and the relationship built during the uncertain phase is what makes that progression smooth.
Doing this well demands close reading of how each insurer's product-liability, recall and technical-indemnity wordings actually define the product, the trigger and the exclusions, because that is where a novel-food placement is won or lost. Sarvada gives commercial insurance brokers structured, searchable access to insurer policy wordings and the intelligence around them, so a broker placing cover for an alt-protein startup can compare definitions, exclusions and conditions across the market instead of taking each wording on trust. Request Access to ground these first-of-kind placements in real wording detail.